Elbow Stiffness Market Share

Elbow Stiffness Market Scenario

The elbow stiffness market is expected to register USD 852 Million at a CAGR  of 6.10% during the forecast period2023 to 2030.

The elbow stiffness market is majorly driven by the high prevalence of rheumatoid arthritis, rise in injuries in the older population, increasing infection rates, rising demand for technical advancements, increasing number of regulatory approvals, and growing penetration by market players. Additionally, factors such as increasing funding for research and development initiatives in advanced medical treatment options are likely to drive the market.

However, factors such as lack of awareness regarding causes of elbow stiffness are likely to hamper the growth of the market.

Market Segmentation   

The elbow stiffness market is segmented on the basis of treatment, diagnosis, and end-user. Considering treatment, the market is segmented into conservative treatment and surgical treatment. Based on conservative treatment, the market is segmented into physiotherapy and splinting. By surgical treatment, the market is segmented into open surgery and arthroscopic procedures. With reference to diagnosis, the market is segmented into X-Ray and MRI.  On account of end-user, the market is segmented into hospitals and clinics, research institutes and ambulatory surgical centers, and others. Based on region, the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

Regional Market Summary

North America is expected to hold the largest share of the elbow stiffness market. The increasing prevalence of arthritis and rise in injuries in older population are likely to enhance the growth of the elbow stiffness industry. Additionally, factors such as increasing government initiatives and funding for research and development in advanced medical treatment options and rising demand for technologically advanced treatments are likely to enhance the growth of the elbow stiffness market in North America. For instance, according to the American College of Rheumatology, in 2017, around 54.4 million adults in the U.S. had arthritis. Additionally, according to the Centers for Disease Control and Prevention, arthritis is the leading cause of disability, aching, stiffness, and swelling of the joints. Similarly, rheumatoid arthritis is estimated to have affected 1.3 million U.S. adults and is likely to affect 78 million adults by 2040.  This growing rate in arthritis disorders is expected to have a direct effect on elbow stiffness as arthritis is a major cause for elbow stiffness.  Additionally, the rising healthcare expenditure for treatments is likely to propel the growth of the elbow stiffness market in the American region.

Europe is the second largest market and holds a healthy share in the global elbow stiffness market. The European market is expected to grow at a strong growth rate during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with growing need for better healthcare infrastructure. Furthermore, increasing prevalence of arthritis, along with the rising older population eventually increasing the patient population are driving the growth of the elbow stiffness market. According to Arthritis and Rheumatism International, in 2015, RMD affected 120 million people in Europe. The increasing prevalence of arthritis and inflammatory joint disorders are expected to propel the elbow stiffness market as joint inflammations are a major cause of elbow stiffness.

Asia Pacific is expected to be the fastest growing market. Factors such as the increasing prevalence of inflammatory disorders and injuries are the major drivers for the market growth. China is expected to be the fastest growing country due to the increasing population and raising awareness about health and availability of new treatment methods. Moreover, increasing healthcare expenditure and rise in the standard of living in the region are driving the growth of the elbow stiffness market in the Asia Pacific region.

The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market share owing to the development of the healthcare industry and rising availability of specialty care centers.

Research Methodology:

Source: World Health Organization, Centers for Disease Control and Prevention, Arthritis Foundation, Rheumatoid Arthritis org, Arthritis Research U.K. expert interview, annual report, white paper, company presentation and market research future analysis

Market Segmentation & Key players

Elbow Stiffness Market, by Treatment

• Conservative Treatment


• Physiotherapy


• Splinting


• Surgical Treatment


• Open Surgery


• Arthroscopic Procedures

Elbow stiffness Market, by Diagnosis

• X-Ray


• MRI

Elbow stiffness Market, by End-user

• Hospitals & Clinics


• Ambulatory Surgical Centers


• Research Institutes


• Others

Elbow stiffness Market, by Region

• North America
  
  
  
  • U.S
  
  
  • Canada
  
  
  
  


• South America


• Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • France
    
    
    • U.K.
    
    
    • Italy
    
    
    • Spain
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  


• Asia Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • Republic of Korea
  
  
  • Rest of Asia Pacific
  
  
  
  


• The Middle East and Africa
  
  
  
  • United Arab Emirates
  
  
  • Saudi Arabia
  
  
  • Oman
  
  
  • Kuwait
  
  
  • Qatar
  
  
  • Rest of the Middle East & Africa
  
  
  
  

Market Players

• AbbVie


• Boehringer Ingelheim GmbH


• Novartis AG


• Regeneron Pharmaceuticals, Inc.


• Pfizer, Inc.


• Bristol-Myers Squibb Company


•  Hoffmann-La Roche Ltd.


• Johnson & Johnson Services, Inc.


• Amgen, Inc.


• Qiagen N.V.


• Siemens Healthcare Scientific Ltd.


• Bio Rad Laboratories Inc.

Intended Audience

• Pharmaceutical Manufacturers and Suppliers


• Medical Research Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors